Clinuvel Has Done Its Reimbursement Homework For Orphan Drug Scenesse, But Can It Make Money?
This article was originally published in The Pink Sheet Daily
As Australia-listed Clinuvel prepares to file its porphyria drug in Europe, it’s confident the orphan treatment will win reimbursement. But the firm will have to exploit larger indications like vitiligo in order to provide a return for investors.
You may also be interested in...
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.